13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001917529
Total reported value
$881.3M
$881.3M
11 檔
62.1%
At the close of Q2 2025, Atlas Venture Life Science Advisors, LLC disclosed equity holdings valued at approximately $881.3M, spread across 11 reported holdings.
During Q2 2025, Atlas Venture Life Science Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including KYMR, IRON, DYN) accounted for 62.1% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc | Stock-Other | 32.26% | -11.21% | — | |
| 2 | IRON | Disc Medicine Inc | Stock-Other | 19.07% | +0.31% | — | |
| 3 | DYN | Dyne Therapeutics Inc | Stock-Other | 13.12% | -3.81% | — | |
| 4 | SION | Sionna Therapeutics Inc | Stock-Other | 9.68% | -0.25% | — | |
| 5 | ✓ | Third Harmonic Bio Inc | Stock-Other | 8.53% | — | — | |
| 6 | VIGL | Vigil Neuroscience Inc | Stock-Other | 7.01% | — | — | |
| 7 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 6.31% | — | — | |
| 8 | KRRO | Korro Bio Inc | Stock-Other | 2.14% | -0.19% | — | |
| 9 | ✓ | Ikena Oncology Inc | Stock-Other | 1.02% | — | — | |
| 10 | QTTB | Q32 Bio Inc | Stock-Other | 0.47% | +2.23% | — | |
| 11 | GBIOGBX | Generation Bio Co | Stock-Other | 0.40% | — | — |
According to official SEC Form 13F filings, Atlas Venture Life Science Advisors, LLC reported a total U.S. public equity portfolio value of $881.3M across 11 disclosed positions in Q2 2025.
During Q2 2025, Atlas Venture Life Science Advisors, LLC's top holdings by market value included KYMR (32.3%)、IRON (19.1%)、DYN (13.1%). The largest single position, KYMR, represented 32.3% of total portfolio value.
In Q2 2025, Atlas Venture Life Science Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.